International Journal of Molecular Medical Science, 2024, Vol.14, No.6, 355-368 http://medscipublisher.com/index.php/ijmms 367 Orme T., Hernandez D., Ross O., Kun-Rodrigues C., Darwent L., Shepherd C., Parkkinen L., Ansorge O., Clark L., Honig L., Marder K., Lemstra A., Rogaeva E., George-Hyslop P., Londos E., Zetterberg H., Morgan K., Troakes C., Al-Sarraj S., Lashley T., Holton J., Compta Y., Deerlin V., Trojanowski J., Serrano G., Beach T., Lesage S., Galasko D., Masliah E., Santana I., Pástor P., Tienari P., Myllykangas L., Oinas M., Révész T., Lees A., Boeve B., Petersen R., Ferman T., Escott-Price V., Graff-Radford N., Cairns N., Morris J., Pickering-Brown S., Mann D., Halliday G., Stone D., Dickson D., Hardy J., Singleton A., Guerreiro R., and Bras J., 2020, Analysis of neurodegenerative disease-causing genes in dementia with Lewy bodies, Acta Neuropathologica Communications, 8: 1-11. https://doi.org/10.1186/s40478-020-0879-z PMid:31996268 PMCid:PMC6990558 Ortega-Rojas J., Arboleda-Bustos C., Guerrero E., Neira J., and Arboleda H., 2022, Genetic variants and haplotypes of TOMM40, APOE, and APOC1 are related to the age of onset of late-onset alzheimer disease in a colombian population, Alzheimer Disease & Associated Disorders, 36: 29-35. https://doi.org/10.1097/WAD.0000000000000477 PMid:35149606 Panza F., Lozupone M., Seripa D., Daniele A., Watling M., Giannelli G., and Imbimbo B., 2020, Development of disease-modifying drugs for frontotemporal dementia spectrum disorders, Nature Reviews Neurology, 16: 213-228. https://doi.org/10.1038/s41582-020-0330-x PMid:32203398 Park J., Kim H., Kim Y., Jang H., Cho S., Kim S., Na D., Won H., Ki C., and Seo S., 2020, Analysis of dementia-related gene variants in APOE ε4 noncarrying Korean patients with early-onset Alzheimer's disease, Neurobiology of Aging, 85: 155.e5-155.e8. https://doi.org/10.1016/j.neurobiolaging.2019.05.009 PMid:31217084 Perrone F., Cacace R., Mossevelde S., Bossche T., Deyn P., Cras P., Engelborghs S., Zee J., and Broeckhoven C., 2018, Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis, Neurobiology of Aging, 69: 292.e7-292.e14. https://doi.org/10.1016/j.neurobiolaging.2018.04.015 PMid:29859640 Prendecki M., Kowalska M., Totoń E., and Kozubski W., 2020, Genetic editing and pharmacogenetics in current and future therapy of neurocognitive disorders, Current Alzheimer research, 17(3): 238-258. https://doi.org/10.2174/1567205017666200422152440 PMid:32321403 Pyun J., Park Y., Lee K., Kim S., Saykin A., and Nho K., 2021, Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment, Translational Neurodegeneration, 10(1): 32. https://doi.org/10.1186/s40035-021-00259-w PMid:34465370 PMCid:PMC8406896 Ramos C., Aguillón D., Cordano C., and Lopera F., 2020, Genetics of dementia: insights from Latin America, Dementia & Neuropsychologia, 14: 223-236. https://doi.org/10.1590/1980-57642020dn14-030004 PMid:32973976 PMCid:PMC7500810 Reitz C., Brayne C., and Mayeux R., 2011, Epidemiology of Alzheimer disease, Nature Reviews Neurology, 7: 137-152. https://doi.org/10.1038/nrneurol.2011.2 PMid:21304480 PMCid:PMC3339565 Saddiki H., Fayosse A., Cognat E., Sabia S., Engelborghs S., Wallon D., Alexopoulos P., Blennow K., Zetterberg H., Parnetti L., Zerr I., Hermann P., Gabelle A., Boada M., Orellana A., Rojas I., Lilamand M., Bjerke M., Broeckhoven C., Farotti L., Salvadori N., Diehl-Schmid J., Grimmer T., Hourrègue C., Dugravot A., Nicolas G., Laplanche J., Lehmann S., Bouaziz-Amar E., Hugon J., Tzourio C., Singh‐Manoux A., Paquet C., and Dumurgier J., 2020, Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker-based case-control study, PLoS Medicine, 17(8): e1003289. https://doi.org/10.1371/journal.pmed.1003289 PMid:32817639 PMCid:PMC7446786 Serrano‐Pozo A., Das S., and Hyman B., 2021, APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches, The Lancet. Neurology, 20: 68-80. https://doi.org/10.1016/S1474-4422(20)30412-9 PMid:33340485 Stocker H., Möllers T., Perna L., and Brenner H., 2018, The genetic risk of Alzheimer’s disease beyond APOE ε4: systematic review of Alzheimer’s genetic risk scores. Translational Psychiatry, 8(1): 166. https://doi.org/10.1038/s41398-018-0221-8 PMid:30143603 PMCid:PMC6109140 Torres A., Jara C., Park-Kang H., Polanco C., Tapia D., Alarcón F., Peña A., Llanquinao J., Vargas-Mardones G., Indo J., Inestrosa N., and Tapia-Rojas C., 2021, Synaptic mitochondria: an early target of amyloid-β and tau in Alzheimer's disease, Journal of Alzheimer's Disease: JAD, 84(4): 1391-1414. https://doi.org/10.3233/JAD-215139 PMid:34719499
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==